Based on cell culture and studies in mice, increased dietary calcium appears to stimulate lipolysis and could possibly reduce body adiposity through hormonal influences on adipocyte calcium uptake. In this study, we investigated the effects of 1,500 mg supplemental calcium daily for 3 months on hormones regulating calcium and energy metabolism and rates of lipid oxidation and lipolysis in overweight women. Fifteen overweight (BMI > 25 kg/rn 2) premenopausal women were supplemented with 1,500 mg of calcium, as CaCO 3, per day for 3 months while maintaining their usual diets and activity levels. Baseline and endpoint measurements were obtained after the subjects consumed a standardized 25% fat diet for 4 days. Lipid oxidation was measured by indirect calorimetry, lipolysis by infusion of deuterated glycerol, and body fat by dual-energy X-ray absorptiometry. Urinary calcium, circulating levels of hormones involved in energy and lipid metabolism (insulin, leptin, and adiponectin) or calcium metabolism (25(OH) D, 1,25(OH) 2 D), and parathyroid hormone (PTH)) were also measured. Urinary levels of calcium (P = 0.005) increased and 1,25(OH) 2 D declined (P = 0.03). However other parameters, including body weight, body fat, PTH, insulin, leptin, adiponectin, 25(OH)D, as well as rates of lipid oxidation and lipolysis were not altered by calcium supplementation. Calcium supplementation for 3 months increased urinary calcium excretion, decreased circulating levels of 1,25(OH) 2 -D, but had no effect on rates of lipid oxidation or lipolysis, in these overweight women.
INTRODUCTION
The prevalence of obesity in adults and children has increased markedly over the past several decades. Thus, it is not surprising that a potential role for dietary calcium in regulating energy metabolism and body fat has attracted considerable attention (1) . Epidemiological, cross-sectional, and longitudinal studies have all reported an inverse relationship between calcium intake and body fat in men, women, and children (2) (3) (4) (5) . In general, the loss of fat was greatest, and more fat was lost from the abdominal area if the source of dietary calcium was from dairy products (1, 3) .
The reported effects of dietary calcium on body weight and fat are not consistent, however, in all human studies. Increased dietary calcium/dairy foods did not affect body weight or fat in 50 overweight men and women (6) , and in a double-blind, randomized, placebo-controlled trial of 100 women supplemented with 1,000mg/day of calcium during a 25-week energyrestricted diet, calcium did not affect the amount of weight or fat lost (7) . Results from animal studies are also inconsistent. Shi et al. (8) reported that mice expressing agouti protein in their white fat lost more weight during an energy-restricted, high-calcium diet compared to the same degree of energy restriction, with low calcium. Similarly Papakonstantinou et al. reported that rats fed high-calcium diet gained significantly less weight than control animals (9) . In contrast, another group studying calcium and weight loss in mice consuming an ad libitum diet did not observe a significant effect of a high-calcium diet (10) .
Although a beneficial effect of calcium and low-fat dairy products on body weight could provide a nutritionally sound way to promote weight loss, such recommendations have not been made, in part because of the conflicting results discussed above, and because the underlying mechanisms that might be involved in the effects of dietary calcium on body weight/ adiposity are poorly understood (1) . Several potential mechanisms have been proposed. First, high intakes of calcium may promote the saponification of dietary fat in the intestine thereby making fat unavailable for absorption. Jacobsen et al. (11) recently reported that increasing dietary calcium from 500 to 1,800 mg/day caused an increase in fecal fat content and fecal energy loss (-350kJ/day). However, the increased fecal energy loss was not associated with a decrease in weight or body fat loss. Second, endocrine effects resulting from higher calcium intake may stimulate adipocyte lipolysis while reducing lipogenesis. Zemel have reported that an increase in dietary calcium downregulated parathyroid hormone (PTH) and 1,25(OH), vitamin D (calcitriol), which decreased adipocyte calcium uptake and inhibited fatty acid synthesis and stimulated lipolysis in cultured adipocytes and in mice. A third proposed mechanism suggests that dairy protein affects the relationship between dietary calcium and weight loss. For example, inhibitors of angmtensin-I-converting enzyme present in whey protein might inhibit angiotensin-JI stimulation of adipocyte lipogenesis (12) . However, compelling evidence that any of these three proposed mechanisms is operative in humans or experimental animals is quite limited.
To investigate the effects of dietary calcium supplementation on energy homeostasis, carbohydrate and fat metabolism in humans, we administered 1,500 mg/day supplemental calcium for 3 months to 15 overweight/obese women and measured rates of lipolysis in adipose tissue, whole-body lipid oxidation, as well as circulating concentrations of several hormones that might be involved in the proposed metabolic effects of calcium supplementation. before enrollment. Subjects had no histor y of medical illnesses, showed no abnormalities on screening physical examination and laboratory testing, had BMIs >25 kg/r&, and had normal serum glucose levels. Enrollment was restricted to young women, because they represent a population with concern about maintaining a healthy body weight.
METHODS AND PROCEDURES Human subjects
Women were excluded if they self-reported any of the following: cigarette smoking, regular use of calcium supplements, previous gestational diabetes, irregular menses, or regular aerobic physical activity, i.e., walk or jog >6 miles/week. A dietary questionnaire (developed b y L. Herraiz and D. Dare, dietitians at the General Clinical Research Center (GCRC) at San Francisco General Flospital) was used to estimate usual calcium intake. Women with intakes >850mg/day were excluded from the study.
Study design
The study was a 3 -month calcium supplementation trial with a set of baseline and endpoint clinical measurements performed at the beginning and end of the study. the women lived at home during the calcium supplementation period and were instructed to maintain their usual physical activity and dietary patterns. Immediately after the baseline measurements, a 3-month supplementation period with 1.5g calcium/ day was initiated. The subjects consumed five 300 mg calcium carbonate tablets (TUMS E-X) daily with meals (three in the morning and two in the evening). Five tablets were packed for each day in 12 weekly pill boxes for the 3-month supplementation period. The pill boxes containing calcium tablets were collected at the end of the study and the compliance was excellent. More than 95% of the pills were consumed.
All clinical procedures were conducted in the GCRC at San Francisco General Hospital during the luteal phase of each womans menstrual cycle (based on subject histories). Before each measurement, a standardized, 2 ) to assure that the women were consuming similar amounts of dietary fat before measuring rates of lipolysis. The diet was based on the food preferences and usual calcium intake of each subject. Energy was adjusted to recommended levels (13); the macronutrient distribution of energy was 60% as carbohydrate, 25% as fat, and 15% as protein. Meals were standardized from day 1 through the end of the measurements/sample collections on day 4. Subjects checked into the GCRC between 4:00 and 5:00 PM on day 3 and were discharged at . 1:00 PM on day 4.
Isotope infusion, clinical measurements, and sample collection
Subjects fasted from 6:00 PM on the evening of day 3 until 8:00 AM on day 4. A baseline blood sample was obtained at 3:45 AM on day 4. Between 4:00 and 8:00 AM ., i,1,2,3,3-[ 2 Hj glycerol was infused at a rate of 0. 11 1.imol/kg/min into an indwelling catheter placed in an antecubital vein at a volume rate of 125 nil/h. The isotope (Isotec, Miamisburg, OH) was highly enriched (^!98%) and was tested for sterility and nonpvrogenicitv before infusion. Blood samples were collected at 7:00 AM for clinical and stable isotope measurements; additional samples collected at 7:30, 7:45, and 8:00 AM were used to measure the dilution of stable isotopes.
Whole-bod y lipid oxidation, nonprotein respiratory quotient (NPRQ), and resting energy expenditure were measured by indirect calorimetry using a Deltatrac metabolic cart (Sensor Mcdix, Yorba Linda, CA) in the hooded mode on day 4 at 7.30 AM (immediately preceding breakfast). Whole-body lipid oxidation, NPRQ, and resting energy expenditure were calculated using the following formulas: (i) whole-body lipid oxidation (mg/kg/mm) = oxygen -(g/min urinary N x 6.25 x 0.966))) + 4.6 x (g/min urinary N x 6.25 x 0.966). Expired air was sampled continuously during the 30-min measurement. Ihe error in oxygen and carbon dioxide reading was under 8%. A 3-h urine sample was obtained from each subject from 6:00 to 9:00 AM for estimating urea nitrogen and determining NPRQ. A 24-h urine sample was obtained from each subject, collected from the morning of day 3 to the morning of day 4 and used for the measurement of urinary calcium.
Body fat was determined using a whole-body dual-energy X-ray absorptiometry scan (System 6781, Model DPX Plus, software version 3.65; Lunar Radiation, Madison, WI) at the GCRC. The scan was performed within a week of the infusion day.
Isolation of metabolites and stable isotope analysis
Because adipose tissue lacks the enz yme glycerol kinase which phosphorylates glycerol released during intracellular Iipolysis, glycerol must be released into circulation and transported to the liver for phosphorylation. The glycerol released from adipose tissue dilutes the infused glycerol isotope and provides a means of estimating the rate of whole-body lipolysis (14) . Glycerol was isolated from the plasma by chromatograph)' on two superimposed anion and cation columns after deproteinization with 70% perchloric acid and then centrifuged. The supernatant containing glycerol was neutralized, isolated by passing through cation and anion resins (15) , frozen, and then lyophilized. The dry powder was reconstituted with 600 l,tl of methanol and dried under N,. The aliquot was then incubated for 15 min at room temperature after adding 100d of acetic anhydride/pyridine (2:1 vol/vol) solution. The solution was dried again under N, and the dry residue was dissolved in 100 p1 of ethyl acetate which converted it to glycerol triacetate to increase volatility and thermal stability for gas chromatography-mass spectrometry (model 5890; Hewlett-Packard, Palo Alto, CA) analysis. Urinary calcium was measured using Inductively Coupled PlasmaAtomic Emission Spectroscopy (Vista; Varian, Walnut Creek, CA). Urinary urea nitrogen and creatinine were determined by enzymatic colorimetric determination (VITROS 950X1; Orthoclinical diagnostics, Rochester, NY) at the GCRC clinical laboratories.
Clinical sample analyses

Statistical analysis
Data are presented as means ± s.d. Relative percent changes were calculated by subtracting the value of the endpoint measurement from that the baseline measurement and multiplying by too. Statistical analyses (Statistical Analysis System (SAS), PC version 8.2; SAS Institute, Car NC) using paired t-tests were performed to test for differences in the physiological responses between baseline and endpoint measurements. Correlations were calculated to determine the association between rates of lipolysis and lipid oxidation and hormone concentrations. Differences were considered statistically significant at P < 0.05.
RESULTS
The characteristics of the participants are described in Table 1 . BMIs of the women ranged from 25 to 33; three subjects had BMI >30. The percent body fat averaged 38% (range: 27-46%); percent body fat of four women exceeded 40%. Calcium intakes averaged 616 mg/day.
Measures of lipid metabolism such as body fat, R , glycerol, and whole-body lipid oxidation, did not change significantly after 12 weeks of calcium supplementation (Table 2) . No change 2402 VOLUME 16 NUMBER 11 NOVEMBER 20081 www.obesityjournat.org in body weight was observed either. Similarly, there were no significant changes of resting energy expenditure or NPRQ.
Plasma concentrations of the calciotropic hormone 1,25(OH),D decreased by 23% from 49.2 ± 32.5 to 38.0 ± 22.6 pg/nil (P = 0.03), however, there were no significant changes in either PTH or 25(OH)D. Similarly, there were no significant changes in the circulating concentrations of the hormones, insulin, adiponeclin, or leptin, which are known to be involved in the regulation of lipid metabolism. Twenty four-hour urinary calcium excretion increased significantl y by 24% from 77.7 ± 49.2 to 96.1 ± 42.9 mg/24h (P = 0.005) after calcium supplementation (Table 3 ).
DISCUSSION
Supplementation with 1,500 mg of calcium a day for 3 months in young overweight or obese women statistically increased 24-h urinary calcium. A significant decrease in 1,25(OH),D was also observed. However, no significant effects on rates of lipolysis, whole-body lipid oxidation, whole-body energy expenditure/NPRQ, body weight, body fat, PTH, 25(OH)D, insulin, leptin, or adiponectin concentrations were observed. Overall, the results of this study do not support the hypothesis that supplementation with 1,500 mg of calcium/day for 3 months in healthy overweight or obese women increases lipolysis.
This is the first study to date to investigate the effects of increased calcium intakes on rates of lipolysis (R glycerol) in human subjects. The rate of glycerol appearance (R glycerol) was unchanged during calcium supplementation suggesting that lipolysis is not influenced by a substantial increase in dietary calcium. Whole-body lipid oxidation, measured by indirect calorimetry, before and after calcium supplementation was also unchanged. Melanson et al. (18) reported that acute total and acute dairy calcium intakes (i.e., calcium intakes in the past 24 h) were positively correlated with 24-h lipid oxidation measured in a whole room indirect calorimeter. However, they found no relationship between habitual total and dairy calcium intake. It is possible that acute changes of calcium intake alter the rates of lipid oxidation, but these rates return to a state of equilibrium within a relatively short period of time.
Of the hormones measured, only plasma 1,25(OH),D, which decreased by 23%, was significantly changed by calcium supplementation. Given that the initial plasma PTH concentrations in the subjects were in the low-normal range, it seems unlikely that calcium supplementation would cause a further decline of PTH (19) . Another possibility is that the 10-h lag period between taking the calcium supplement and blood sampling decreased the ability to detect effects on PTH. Intact PTH has a half-life of only a few minutes (20), and in a recent study by Ortolani el al., a maximal decrease of PTH secretion was observed 2 h after calcium intake (21) .
In the present study, fasting serum insulin concentrations were unchanged during calcium supplementation. This differs from the results reported by Sanchez et al. (22) who studied nondiahetic, hypertensive older men (mean age 45 years). Because none of the women in the present study were hypertensive, it is possible that differences in the populations, including gender, studied may account for the different responses to calcium supplementation observed between the two studies. To our knowledge, there are no published studies investigating whether circulating leptin and adiponectin concentrations are influenced by increased calcium intakes in humans. Neither the small increase of adiponectin nor the decrease of leptin observed in the study was significant.
Twenty four-hour urinary calcium increased by 24%, indicating compliance with calcium supplementation. In addition, body weight or body fat did not decrease after 12 weeks of calcium supplementation. 'Ihis was not unexpected because the study was not designed to be powered to detect changes of body weight or adiposity. Data analyzed by Heaney et al. (23) suggest that for both middle aged and older women, a calcium intake difference of 300 mg/day is associated with weight loss in the range of 0.11-0.16kg/year. Extrapolating this data to include younger women, an addition of 1,500 mg of calcium a day for 3 months could lead to weight losses of up to 0.20 kg. This marginal weight loss would not be expected to he statistically significant in a study that included only 15 subjects.
Although we observed no effects of increased calcium intakes on lipolysis, it is possible that other factors that were not taken into consideration in the present study may have influenced the outcome. The subjects in the study had on average, fasting glucose, P'IH, 25(OH)D, and insulin levels close to the lower end of the normal range. It is possible that changes in the endpoints measured may be more discernable among individuals with chronically elevated levels of these hormones and metabolites (indicating a more metabolically impaired state). The minimum amount of dietary calcium required to induce a metabolic shift in substrate utilization and energy expenditure may be an important factor in determining these relationships. Currently available data are insufficient to define this threshold. It is possible that the subject's mean baseline calcium intakes of 616mg/day in this study were above this threshold value. A third factor that may play an important role is the source of calcium in the diet. Zemel (24) reported that dairy calcium sources have a greater effect than nondairy calcium sources, and they have hypothesized that other factors present in milk/ dairy products contribute to or work together with calcium in the reported effects dairy foods to induce weight loss.
In conclusion, the present study conducted in young overweight to obese healthy women did not replicate previous findings reported in transgenic agouti mice (8) that increased dietary calciuni independently increases rates of lipolysis. We found that increased calcium intakes (1,500mg of calcium a day for 3 months) in overweight or obese women did not shift lipid metabolism in a manner that would be expected to result in weight loss over the long-term (i.e., toward lipolvsis) through effects on the PTH!1,25(OH)D axis. 
